Latest Innovation News

Lincoln Minerals has entered a collaboration with SCN Canada to explore the use of its high-purity graphite in small modular nuclear reactors, aiming to tap into emerging clean energy markets.

PointsBet Holdings Limited has appointed Andrew Catterall as Group CEO effective February 2026, with founder Sam Swanell transitioning to an advisory role while remaining on the Board.

Nanoveu’s subsidiary EMASS has completed the design phase of its cutting-edge 16nm ECS-DoT Edge AI system-on-chip, moving closer to fabrication and silicon validation that could redefine ultra-low-power AI at the edge.

Brazilian Critical Minerals Ltd has produced a high-grade mixed rare earth carbonate with 52.5% total rare earth oxides and 41.5% magnet rare earth oxides from its Ema Project field trials, validating a low-capital in-situ recovery process.

Talga Group launches a $5 million Share Purchase Plan at a discounted price of $0.41 per share, offering eligible shareholders free attaching options as it advances its battery anode production expansion.

Harmoney Corp Limited reported a staggering 742% increase in Cash NPAT for FY25, driven by its new Stellare® 2.0 platform and operational efficiencies. The company reaffirmed its ambitious $12 million profit target for FY26 while unveiling a secured car loan product and securing a major bank debt facility.

Locate Technologies has completed its redomiciliation from Australia to New Zealand, establishing Locate NZ as the new parent company and appointing MUFG Pension & Market Services as its share registry provider.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.

Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

Anson Resources and POSCO Holdings have advanced their collaboration on the Green River Direct Lithium Extraction demonstration plant, with POSCO’s investment decision timeline pushed to early 2026. The partnership signals a strategic move to secure North American lithium resources and commercialize cutting-edge extraction technology.